ABSCI CORP

AbSci Corporation launches a global Phase 2 study of AI‑designed ABS‑201, a non‑hormonal antibody targeting the prolactin receptor to reduce pain from endometriosis and offer a new, precise therapy for millions of women worldwide.

AbSci Corporation, a Vancouver‑based synthetic biology leader, offers a one‑stop platform that streamlines biologic drug discovery, cutting time and costs while boosting patient outcomes.

AbSci Corporation, a synthetic biology company, is revolutionizing biologic drug discovery and development with its integrated platform, despite facing financial challenges typical of the biotech industry.

Absci Corporation, a synthetic biology company, reported Q2 2025 financials with a slight improvement in quarterly loss per share and a 4.72% reduction in revenue, but analysts remain optimistic about its potential for growth and innovation.

AbSci Corporation is a pioneering synthetic biology company revolutionizing biologic drug discovery and development with its integrated platform, aiming to transform the healthcare sector.

Absci Corporation has announced a milestone in its clinical trial of ABS-101, a potential treatment for Inflammatory Bowel Disease, and reported stronger-than-expected financial performance for Q1 2025.